Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Cd-12 = Best covid-19 therapeutic by a Tennessee m

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154037
(Total Views: 582)
Posted On: 03/06/2021 4:54:29 AM
Posted By: onestepahead
Cd-12 = Best covid-19 therapeutic by a Tennessee mile. Gold standard trial and the shorts and day flippers are posting 20 times each their negative personal agenda opinions. Yes the trial included only 62 critical patients but how many severed were stopped from moving into the critical stage. CYDY was taking patients at a 2-1 ratio so at most there was 260 leronlimab vs 130 SOC placebo.

Severed were not progressing to critical fast enough because of the soc and criticals were being kept alive longer due to dexa? The day 28 maybe the biggest factor in numbers being lower than for example all cause mortality at day 42 or even better at day 60. The statistic about being 166% better chance of walking of out hospital at day 28 tells the story. And the reduction in hospital stay by 6 days are very significant. Pvalue .005 even on smaller population of criticals is an AMAZING STAT. Someone pointed out insurance companies and hospitals would love to clear the beds and let people be able to be discharged 6 days earlier. This will get approval based on that stat alone it will save the insurance companies $10,000+ a night per each critical covid patient. I’m sure it’s helping the severes not move into the critical stage so my belief is other data will show significant decline of moving into critical from severe for leronlimab side calls SOC placebo. Looking forward to Monday’s conference call and getting more info on the discussions with all the countries.

The shorts came out in full force tonight to make everyone question the results. I would hope the mods delete 80% of this crap in the morning. Way to much negative speculation.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us